PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER
Prostate cancer treatment & diagnosis
Primary Objectives to determine whether SBRT can be shown to be superior to hypofractionated IMRT in terms of GU and GI toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel HRQOL.
Dr. Michael I. Ghilezan
Radiation OncologistWorks at 4 centers.
Dr. Larry L. Kestin
Radiation OncologistWorks at 3 centers.
Dr. Kay T. Miller
Radiation OncologistClarkston (Radiation oncology)
Dr. Frank A. Vicini
MD, FACR, FASTRO
Radiation oncologistWorks at 3 centers.
Warning: count(): Parameter must be an array or an object that implements Countable in /var/www/html/wp-content/themes/genesiscare/src/components/hcp_clinical_trial_heading/hcp_clinical_trial_heading.php on line 299
Warning: Invalid argument supplied for foreach() in /var/www/html/wp-content/themes/genesiscare/src/components/hcp_clinical_trial_heading/hcp_clinical_trial_heading.php on line 301